Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported disappointing financial results with significant revenue and profit declines, resulting in a net loss. Despite optimistic guidance and international expansion plans, uncertainties like the largest customer's exclusion from projections, unclear FDA approval timelines, and vague management responses during the Q&A raise concerns. Increased expenses and negative EBITDA further contribute to a negative sentiment. Although there is potential in international markets and reimbursement changes, the overall outlook remains negative due to financial underperformance and uncertainties.
Key Financial Performance
Revenues (Q4 2025) $4.9 million, compared with $3.1 million in Q4 2024. This represents an increase, primarily driven by revenue recognized from new placements under the Fair Deal Agreement program, despite a lower number of units sold.
Cost of Sales (Q4 2025) $3 million, compared to $6 million in Q4 2024. The decrease was primarily related to a lower number of units sold, offset by higher cost of service and costs associated with placement under the FDA program.
Gross Profit (Q4 2025) $1.9 million or 38.8% of revenues, compared with $7.1 million or 54.2% of revenues in Q4 2024. The decrease was driven by lower sales, higher cost of servicing systems, and costs associated with the new placement under the FDA program.
General and Administrative Expenses (Q4 2025) $1.8 million, compared with $2.4 million in Q4 2024. The decrease was due to lower professional fees and compensation costs.
Selling and Marketing Expenses (Q4 2025) $1.4 million, consistent with Q4 2024.
Research and Development Expenses (Q4 2025) $1.9 million, compared with $1.6 million in Q4 2024. The increase was due to higher product development costs related to next-generation systems.
Net Loss (Q4 2025) $3.2 million or a loss of $0.19 per share, compared with a net income of $1.5 million or $0.09 per diluted share in Q4 2024. The decline reflects the net loss in the current quarter compared to net income in the prior year period.
Adjusted EBITDA (Q4 2025) Negative $3 million, compared with $1.9 million in Q4 2024. The decline reflects the net loss in the current quarter compared to net income in the prior year period.
Revenues (Full Year 2025) $27.5 million, compared with $41.8 million in 2024. The decrease was driven by a lower number of units sold, reflecting reduced sales to the largest customer, slightly offset by revenue recognized from new placements under the FDA program.
Cost of Sales (Full Year 2025) $15.6 million, compared with $17.4 million in 2024. The decrease was related to lower unit volumes, partially offset by higher cost of service and costs associated with the new placements under the FDA program.
Gross Profit (Full Year 2025) $11.9 million or 43.3% of revenues, compared with $24.4 million or 58.4% of revenues in 2024. The decrease was driven by lower sales volumes, higher servicing costs, and FDA program-related expenses.
General and Administrative Expenses (Full Year 2025) $7.9 million, compared with $7.1 million in 2024. The increase was due to higher professional fees, insurance costs, and compensation.
Selling and Marketing Expenses (Full Year 2025) $6.5 million, compared with $5 million in 2024. The increase was driven by higher travel costs and increased payroll expenses associated with higher headcount.
Research and Development Expenses (Full Year 2025) $7.8 million, compared with $4.2 million in 2024. The increase was due to significant legal costs related to billing code reimbursement efforts, increased headcount, and higher product development costs related to next-generation systems.
Net Loss (Full Year 2025) $7.7 million or a loss of $0.47 per share, compared with net income of $6.6 million or $0.41 per diluted share in 2024. The decline reflects the net loss in the current year compared to net income in the prior year.
Adjusted EBITDA (Full Year 2025) Negative $9.6 million, compared with $8.7 million in 2024. The decline reflects the net loss in the current year compared to net income in the prior year.
Cash and Cash Equivalents (End of 2025) $22.1 million, unchanged from the year-end 2024, with no outstanding borrowings under the revolving line of credit.
Inventories (End of 2025) $14.6 million, compared with $10.1 million in 2024, reflecting inventory build in support of anticipated future demand.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New CPT Codes for SRT and IG-SRT: Sensus Healthcare's SRT and IG-SRT technology received exclusive and dedicated CPT codes, ensuring clear reimbursement for treating non-melanoma skin cancer. This development is expected to drive adoption and provide a noninvasive alternative to surgery.
Next-Generation Systems: Increased R&D expenses were reported due to higher product development costs related to next-generation systems.
International Expansion: International demand grew, with six systems shipped internationally in Q4, including to China. International markets are seen as attractive due to lower installation and servicing costs and are a key part of the growth strategy.
MDSAP Certification: The certification is expected to diversify international opportunities and expand market reach.
Fair Deal Agreement Program: The program ended the year with 18 active FDA sites and 10 pending activation. Utilization increased substantially, with treatments up eightfold and patients treated up by 250% year-over-year.
Sales Force Expansion: Plans to hire 3-5 additional sales representatives in 2026 to increase market education and accelerate lead conversions.
Customer Base Diversification: Shift away from reliance on a single large customer to a more diversified customer base, reducing risk and improving revenue predictability.
Refined Trade Show Strategy: Focus on high-yield national and regional meetings to generate quality leads and decision-maker engagement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Customer Concentration: The company has historically relied heavily on a single large customer for sales, which has impacted revenue when sales to this customer declined. Although efforts are being made to diversify the customer base, this remains a potential risk.
Reimbursement Uncertainty: While new CPT codes have been introduced, the adoption and understanding of these codes by physicians and practices may take time, potentially delaying revenue growth.
International Market Risks: Although international sales are growing, they come with risks such as geopolitical uncertainties, regulatory challenges, and potential trade restrictions, especially in markets like China.
Cost of Servicing Systems: Higher servicing costs for systems and costs associated with FDA program placements have negatively impacted gross margins.
R&D and Legal Costs: Increased research and development expenses, as well as significant legal costs related to billing code reimbursement efforts, have contributed to financial losses.
Inventory Management: The company has increased its inventory levels in anticipation of future demand, which could lead to financial strain if demand does not materialize as expected.
Scaling Sales Organization: Plans to expand the sales team and increase market education require upfront investment, which may not yield immediate returns.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects Q1 2026 revenues to exceed Q4 2025 revenues and aims to achieve full-year profitability in 2026.
Market Trends and Adoption: Reimbursement certainty and attractive economics are expected to drive adoption of SRT technology, particularly among small and midsized practices. International demand, especially in China, is anticipated to grow, supported by MDSAP certification.
Sales and Commercial Strategy: The company plans to expand its sales force by hiring 3 to 5 additional representatives in 2026 to increase market education and accelerate lead conversions. A more targeted trade show and conference strategy will focus on high-quality lead generation.
Operational Changes: The company is transitioning to a more diversified customer base and reducing reliance on a single large customer. It is also focusing on direct sales and shared services with end users.
Profitability and Growth: Sensus aims to scale more efficiently with improved visibility, stronger economics, and a broader set of monetization levers. The company expects international markets to remain a key component of its growth strategy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Does the guidance for sequential growth in the first quarter revenue growth assume contributions from the largest customer?
A:The guidance does not include any expectations from the largest customer. The company has excluded them from projections for 2026 as they need to reevaluate their model. Any contributions from them would be considered an upside.
Q:Is there any update on TDI and its FDA approval timeline?
A:The company is working closely with the FDA but does not have a clear timeline for approval. They are continuing to pursue the matter despite challenges.
Q:What is the demand outlook internationally, and are there any specific countries showing promise or concerns for 2026?
A:China remains the largest international market, with growing demand in Taiwan, South Korea, and Japan. The Middle East, India, and South America, particularly Brazil, are also showing potential. The company expects to gain regulatory clearance in Brazil this year.
Q:What is the reaction to reimbursement changes, and how does it affect system mix and financing options?
A:Reimbursement certainty has led to shifts in customer preferences. Smaller centers prefer purchasing or leasing equipment rather than revenue-sharing models. The SRT-100 product is favored due to cost savings and better margins. Private equity-backed groups are reevaluating their acquisition strategies.
Q:Has there been any change in interest from private equity-backed groups due to reimbursement certainty?
A:Interest has increased, with more groups considering the device and skin cancer market. The black-and-white coding environment has made it easier for customers to commit.
Q:What is the status of Sentinel 2.0, and how will it be rolled out?
A:Sentinel 2.0 is progressing well and will be rolled out broadly in the near future.
Q:What is the outlook for service revenue?
A:Service revenue remains at 10% of the company's total revenue, with no changes expected.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear timeline for TDI's FDA approval, citing challenges with the FDA's understanding. Additionally, details on Sentinel 2.0's rollout were vague, with no specific timeline or strategy provided.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agreement program
CMS code
CPT code
Chief Commercial
Commercial Officer
Deal Agreement
Fair Deal
IG SRT
Officer General
President Chief
Revenues decrease
SRT IG
SRT technology
component
cost service
customer base
customer placement
decrease number
development increase
economics
factor
income net
news CMS
number unit
physician reimbursement
placement FDA
program Cost
program revenue
reimbursement clarity
sale customer
sale decrease
service placement
servicing
system placement
system shipment
technology CPT
unit sale
SRTS Transcript
Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript
Unknown2-12
The company reported disappointing financial results with significant revenue and profit declines, resulting in a net loss. Despite optimistic guidance and international expansion plans, uncertainties like the largest customer's exclusion from projections, unclear FDA approval timelines, and vague management responses during the Q&A raise concerns. Increased expenses and negative EBITDA further contribute to a negative sentiment. Although there is potential in international markets and reimbursement changes, the overall outlook remains negative due to financial underperformance and uncertainties.
Sensus Healthcare, Inc. (SRTS) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call reveals declining financial metrics, including reduced units sold, gross profit, and increased net loss, indicating weakening financial health. Despite some positive elements, like international expansion and potential breakeven in Q4, the negative trends, including a significant drop in gross margin and increased operating expenses, dominate. The Q&A section did not alleviate concerns, as management's responses lacked clarity on critical timelines. Given these factors, the stock is likely to experience a negative reaction in the near term.
Sensus Healthcare, Inc. (SRTS) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call revealed significant declines in gross profit, gross margin, and a shift from net income to net loss, indicating financial challenges. The Q&A highlighted uncertainties around CMS reimbursement, impacting sales and causing a large customer to pause purchases. Despite some international sales optimism, the lack of clear guidance on reimbursement and increased operating expenses suggest a negative short-term outlook. The overall sentiment leans negative due to financial performance issues and unresolved reimbursement concerns.
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q1 2025 Earnings Call Transcript
Unknown5-17
The earnings call summary reflects several concerns: declining revenue, increased operating expenses, and a net loss compared to the previous year. While management expects future profitability, lack of formal guidance and reliance on a few key customers pose risks. No shareholder return initiatives were announced, and competitive pressures remain. Despite some positive aspects like cash position and international expansion, the overall sentiment is negative, as financial metrics are weak, and uncertainties in market demand persist.
SRTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
